402 related articles for article (PubMed ID: 25751647)
21. Role of Immune Therapies for Myeloma.
Rosenblatt J; Avigan D
J Natl Compr Canc Netw; 2015 Nov; 13(11):1440-7. PubMed ID: 26553769
[TBL] [Abstract][Full Text] [Related]
22. Recent advances in understanding multiple myeloma.
Hari P
Hematol Oncol Stem Cell Ther; 2017 Dec; 10(4):267-271. PubMed ID: 28633036
[TBL] [Abstract][Full Text] [Related]
23. Partial T cell-depleted allogeneic stem cell transplantation following reduced-intensity conditioning creates a platform for immunotherapy with donor lymphocyte infusion and recipient dendritic cell vaccination in multiple myeloma.
Levenga H; Schaap N; Maas F; Esendam B; Fredrix H; Greupink-Draaisma A; de Witte T; Dolstra H; Raymakers R
Biol Blood Marrow Transplant; 2010 Mar; 16(3):320-32. PubMed ID: 19835972
[TBL] [Abstract][Full Text] [Related]
24. Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet?
Epperla N; Fenske TS; Lazarus HM; Hamadani M
Bone Marrow Transplant; 2015 Nov; 50(11):1393-404. PubMed ID: 26281033
[TBL] [Abstract][Full Text] [Related]
25. Immunotherapy in multiple myeloma--possibility or probability?
Harrison SJ; Cook G
Br J Haematol; 2005 Aug; 130(3):344-62. PubMed ID: 16042684
[TBL] [Abstract][Full Text] [Related]
26. What is the future of immunotherapy in multiple myeloma?
Rasche L; Hudecek M; Einsele H
Blood; 2020 Nov; 136(22):2491-2497. PubMed ID: 32735639
[TBL] [Abstract][Full Text] [Related]
27. Treatment of multiple myeloma.
San Miguel JF; Bladé Creixenti J; García-Sanz R
Haematologica; 1999 Jan; 84(1):36-58. PubMed ID: 10091392
[TBL] [Abstract][Full Text] [Related]
28. Immunotherapy in multiple myeloma: current strategies and future prospects.
Yi Q
Expert Rev Vaccines; 2003 Jun; 2(3):391-8. PubMed ID: 12903804
[TBL] [Abstract][Full Text] [Related]
29. Cellular immunotherapy for plasma cell myeloma.
Garfall AL; Vogl DT; Weiss BM; Stadtmauer EA
Bone Marrow Transplant; 2013 Nov; 48(11):1377-86. PubMed ID: 23645169
[TBL] [Abstract][Full Text] [Related]
30. Immunotherapy for multiple myeloma.
Rosenblatt J; Bar-Natan M; Munshi NC; Avigan DE
Expert Rev Hematol; 2014 Feb; 7(1):91-6. PubMed ID: 24417573
[TBL] [Abstract][Full Text] [Related]
31. Dendritic cell vaccines in the treatment of multiple myeloma: advances and limitations.
Büchler T; Hajek R
Med Oncol; 2002; 19(4):213-8. PubMed ID: 12512914
[TBL] [Abstract][Full Text] [Related]
32. Immunotherapy using dendritic cells against multiple myeloma: how to improve?
Nguyen-Pham TN; Lee YK; Kim HJ; Lee JJ
Clin Dev Immunol; 2012; 2012():397648. PubMed ID: 22481968
[TBL] [Abstract][Full Text] [Related]
33. Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma.
Neelapu SS; Munshi NC; Jagannath S; Watson TM; Pennington R; Reynolds C; Barlogie B; Kwak LW
Bone Marrow Transplant; 2005 Aug; 36(4):315-23. PubMed ID: 15968284
[TBL] [Abstract][Full Text] [Related]
34. The current status of hematopoietic stem cell transplantation for multiple myeloma.
Bensinger WI
Clin Adv Hematol Oncol; 2004 Jan; 2(1):46-52. PubMed ID: 16163159
[TBL] [Abstract][Full Text] [Related]
35. Mucin 1-specific active cancer immunotherapy with tecemotide (L-BLP25) in patients with multiple myeloma: an exploratory study.
Rossmann E; Österborg A; Löfvenberg E; Choudhury A; Forssmann U; von Heydebreck A; Schröder A; Mellstedt H
Hum Vaccin Immunother; 2014; 10(11):3394-408. PubMed ID: 25483677
[TBL] [Abstract][Full Text] [Related]
36. Novel Immunotherapeutic Agents for the Treatment of Multiple Myeloma.
Rafei H; Haroun F; Tabbara IA
Am J Clin Oncol; 2019 Mar; 42(3):317-329. PubMed ID: 30557165
[TBL] [Abstract][Full Text] [Related]
37. T cell-based targeted immunotherapies for patients with multiple myeloma.
Wang L; Jin N; Schmitt A; Greiner J; Malcherek G; Hundemer M; Mani J; Hose D; Raab MS; Ho AD; Chen BA; Goldschmidt H; Schmitt M
Int J Cancer; 2015 Apr; 136(8):1751-68. PubMed ID: 25195787
[TBL] [Abstract][Full Text] [Related]
38. Autologous graft-versus-host disease: harnessing anti-tumor immunity through impaired self-tolerance.
Kline J; Subbiah S; Lazarus HM; van Besien K
Bone Marrow Transplant; 2008 Mar; 41(6):505-13. PubMed ID: 18026144
[TBL] [Abstract][Full Text] [Related]
39. Long-term outcomes following myeloablative allogeneic transplantation for multiple myeloma compared to autologous transplantation and the impact of graft-versus-myeloma effect.
Khaled Y; Mellacheruvu S; Reddy P; Peres E; Mineishi S
Bone Marrow Transplant; 2009 Sep; 44(5):325-6. PubMed ID: 19204708
[No Abstract] [Full Text] [Related]
40. The immunotherapy era of myeloma: monoclonal antibodies, vaccines, and adoptive T-cell therapies.
Hoyos V; Borrello I
Blood; 2016 Sep; 128(13):1679-87. PubMed ID: 27506540
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
